Androgen supplementation in assisted reproduction: where are we in 2019?

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Standard

Androgen supplementation in assisted reproduction : where are we in 2019? / Montoya-Botero, Pedro; Rodriguez-Purata, Jorge; Polyzos, Nikolaos P.

I: Current Opinion in Obstetrics & Gynecology, Bind 31, Nr. 3, 06.2019, s. 188-194.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Harvard

Montoya-Botero, P, Rodriguez-Purata, J & Polyzos, NP 2019, 'Androgen supplementation in assisted reproduction: where are we in 2019?', Current Opinion in Obstetrics & Gynecology, bind 31, nr. 3, s. 188-194. https://doi.org/10.1097/GCO.0000000000000532

APA

Montoya-Botero, P., Rodriguez-Purata, J., & Polyzos, N. P. (2019). Androgen supplementation in assisted reproduction: where are we in 2019? Current Opinion in Obstetrics & Gynecology, 31(3), 188-194. https://doi.org/10.1097/GCO.0000000000000532

CBE

Montoya-Botero P, Rodriguez-Purata J, Polyzos NP. 2019. Androgen supplementation in assisted reproduction: where are we in 2019?. Current Opinion in Obstetrics & Gynecology. 31(3):188-194. https://doi.org/10.1097/GCO.0000000000000532

MLA

Montoya-Botero, Pedro, Jorge Rodriguez-Purata og Nikolaos P. Polyzos. "Androgen supplementation in assisted reproduction: where are we in 2019?". Current Opinion in Obstetrics & Gynecology. 2019, 31(3). 188-194. https://doi.org/10.1097/GCO.0000000000000532

Vancouver

Montoya-Botero P, Rodriguez-Purata J, Polyzos NP. Androgen supplementation in assisted reproduction: where are we in 2019? Current Opinion in Obstetrics & Gynecology. 2019 jun;31(3):188-194. https://doi.org/10.1097/GCO.0000000000000532

Author

Montoya-Botero, Pedro ; Rodriguez-Purata, Jorge ; Polyzos, Nikolaos P. / Androgen supplementation in assisted reproduction : where are we in 2019?. I: Current Opinion in Obstetrics & Gynecology. 2019 ; Bind 31, Nr. 3. s. 188-194.

Bibtex

@article{0023ea6a03274b1e8061313dd897d2e8,
title = "Androgen supplementation in assisted reproduction: where are we in 2019?",
abstract = "Purpose of reviewThe purpose of this review is to provide an overview of androgen supplementation in ART with the most updated evidence, from animal studies to its clinical applications in poor ovarian responders (POR) and the future studies to be published.Recent findingsAnimal studies, has shown that testosterone supplementation, can be an option to increase the recruitable follicular pool in POR. However, the potential mechanism of action, dose, and duration of treatment is still under investigation. Early studies in humans reported promising results in favor of androgens [dehydroepiandrosterone (DHEA) or testosterone] in POR. Nevertheless, recent evidence does not appear to follow the initial results, whereas the type, dose, and duration of testosterone administration appear to be crucial for treatment effect.SummaryTestosterone seems to play an essential role in regulating ovarian function. However, it is worrisome that androgens are used off-label, despite that the available evidence is weak. Although testosterone supplementation may be beneficial in POR, published studies have used inconsistent doses and duration of administration. An ongoing trial (T-TRANSPORT trial) for the first time aims to provide conclusive evidence on whether transdermal testosterone administration can improve the reproductive outcomes in patients undergoing IVF/ICSI.",
keywords = "androgen, dehydroepiandrosterone, in-vitro fertilization, poor ovarian responder, testosterone, POLYCYSTIC-OVARY-SYNDROME, IN-VITRO FERTILIZATION, POOR RESPONDERS, TRANSDERMAL TESTOSTERONE, DOUBLE-BLIND, FOLLICULAR DEVELOPMENT, CONTROLLED-TRIAL, DEHYDROEPIANDROSTERONE, WOMEN, MARKERS",
author = "Pedro Montoya-Botero and Jorge Rodriguez-Purata and Polyzos, {Nikolaos P.}",
year = "2019",
month = jun,
doi = "10.1097/GCO.0000000000000532",
language = "English",
volume = "31",
pages = "188--194",
journal = "Current Opinion in Obstetrics & Gynecology",
issn = "1040-872X",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "3",

}

RIS

TY - JOUR

T1 - Androgen supplementation in assisted reproduction

T2 - where are we in 2019?

AU - Montoya-Botero, Pedro

AU - Rodriguez-Purata, Jorge

AU - Polyzos, Nikolaos P.

PY - 2019/6

Y1 - 2019/6

N2 - Purpose of reviewThe purpose of this review is to provide an overview of androgen supplementation in ART with the most updated evidence, from animal studies to its clinical applications in poor ovarian responders (POR) and the future studies to be published.Recent findingsAnimal studies, has shown that testosterone supplementation, can be an option to increase the recruitable follicular pool in POR. However, the potential mechanism of action, dose, and duration of treatment is still under investigation. Early studies in humans reported promising results in favor of androgens [dehydroepiandrosterone (DHEA) or testosterone] in POR. Nevertheless, recent evidence does not appear to follow the initial results, whereas the type, dose, and duration of testosterone administration appear to be crucial for treatment effect.SummaryTestosterone seems to play an essential role in regulating ovarian function. However, it is worrisome that androgens are used off-label, despite that the available evidence is weak. Although testosterone supplementation may be beneficial in POR, published studies have used inconsistent doses and duration of administration. An ongoing trial (T-TRANSPORT trial) for the first time aims to provide conclusive evidence on whether transdermal testosterone administration can improve the reproductive outcomes in patients undergoing IVF/ICSI.

AB - Purpose of reviewThe purpose of this review is to provide an overview of androgen supplementation in ART with the most updated evidence, from animal studies to its clinical applications in poor ovarian responders (POR) and the future studies to be published.Recent findingsAnimal studies, has shown that testosterone supplementation, can be an option to increase the recruitable follicular pool in POR. However, the potential mechanism of action, dose, and duration of treatment is still under investigation. Early studies in humans reported promising results in favor of androgens [dehydroepiandrosterone (DHEA) or testosterone] in POR. Nevertheless, recent evidence does not appear to follow the initial results, whereas the type, dose, and duration of testosterone administration appear to be crucial for treatment effect.SummaryTestosterone seems to play an essential role in regulating ovarian function. However, it is worrisome that androgens are used off-label, despite that the available evidence is weak. Although testosterone supplementation may be beneficial in POR, published studies have used inconsistent doses and duration of administration. An ongoing trial (T-TRANSPORT trial) for the first time aims to provide conclusive evidence on whether transdermal testosterone administration can improve the reproductive outcomes in patients undergoing IVF/ICSI.

KW - androgen

KW - dehydroepiandrosterone

KW - in-vitro fertilization

KW - poor ovarian responder

KW - testosterone

KW - POLYCYSTIC-OVARY-SYNDROME

KW - IN-VITRO FERTILIZATION

KW - POOR RESPONDERS

KW - TRANSDERMAL TESTOSTERONE

KW - DOUBLE-BLIND

KW - FOLLICULAR DEVELOPMENT

KW - CONTROLLED-TRIAL

KW - DEHYDROEPIANDROSTERONE

KW - WOMEN

KW - MARKERS

U2 - 10.1097/GCO.0000000000000532

DO - 10.1097/GCO.0000000000000532

M3 - Review

C2 - 30855291

VL - 31

SP - 188

EP - 194

JO - Current Opinion in Obstetrics & Gynecology

JF - Current Opinion in Obstetrics & Gynecology

SN - 1040-872X

IS - 3

ER -